梯瓦製藥 TEVA 深滬

已收盤 09-19 16:00:00 美东时间

18.35

-0.100

-0.54%

華盛通

立即下載

最高18.59
今開18.49
成交量 743.62万股
最低 18.26
昨收 18.45
總市值 210.47亿
52周最高 22.80
市盈率 ^靜 --
換手率 0.65%
52周最低 12.465
委比 -98.62%
總股本 11.47亿
歷史最高 69.8535
量比 0.72
振幅 1.79%
歷史最低 6.07
每手 1
風險率 1.91%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

AUSTEDO XR showed strong efficacy and satisfaction in treating tardive dyskinesia (TD), with >94% of 209 surveyed patients reporting movement improvement, >89% expressing satisfaction, and >96% finding the medication easy to take. Results were presented at the 2025 Psych Congress Annual Meeting, showcasing AUSTEDO XR's positive impact on patients' physical, social, and emotional well-being. The drug, developed by Teva Pharmaceuticals, is the firs...

09-21 02:16
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Teva announced positive data from the SOLARIS trial for olanzapine LAI (TEV-'749), showing no incidence of PDSS and a consistent safety profile with other olanzapine formulations. UZEDY (risperidone) demonstrated shorter hospital stays and higher HCP preference compared to Invega Sustenna. Teva remains committed to advancing innovative treatments for mental health conditions.

09-21 02:15
Countdown Begins: LEAD3R's Healthy Team Summit Under a Month Out

BOSTON, Sept. 17, 2025 /PRNewswire/ -- In just over a month, Boston will host a...

09-17 19:07
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Teva Pharmaceutical Industries Ltd. will present data from its completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting in San Diego, September 17-21, 2025. The company will also host a conference call for analysts and investors on September 22, 2025, at 11:00 a.m. ET. Registration for the call and details for accessing the live webcast are available via the provided links. An archived webcast will be available within 24 hours.

09-16 20:30
Global Psychotic Disorders Market Poised For Significant Growth

The global market for medications addressing psychotic disorders is projected t...

09-16 17:09
Insider trades: Salesforce, Broadcom among notable names this week

Companies including Salesforce (NYSE:CRM) and Broadcom (NASDAQ:AVGO) witnessed major insider transactions this week. The following is a list of deals that took place between September 8 and September ...

09-13 23:03
Riot, D-Wave, AmEx, Lowe’s, Teva: Stock Shake-Up!

Insiders have been trading these 5 stocks: (($RIOT)), (($QBTS)), (($AXP)), (($L...

09-13 21:00
FDA Grants Teva Pharmaceutical's Emrusolmin Fast Track Designation For Multiple System Atrophy

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development.New therapeutic options

09-09 20:31
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Teva Pharmaceutical Industries Ltd. has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy emrusolmin (TEV-56286) to treat Multiple System Atrophy (MSA). Emrusolmin targets alpha-synuclein protein oligomers and is currently in Phase 2 clinical trials. MSA is a rare, progressive neurodegenerative disorder with no cure, affecting approximately 40,000 people in the U.S., EU, and Japan. Th...

09-09 12:30
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

Teva Pharmaceuticals announced the FDA approval and U.S. launch of the first-ever generic GLP-1 product, Saxenda, for weight loss. This marks Teva's commitment to its complex generics portfolio and growth strategy. The generic version of liraglutide injection is indicated for adults with obesity or overweight with weight-related medical problems, and pediatric patients aged 12-17 years with obesity. It comes with important safety considerations, ...

08-28 12:30

派息除權日	每股總股息	派息日期
2017-11-27	0.07	2017-12-12
2017-08-25	0.07	2017-09-14
2017-06-01	0.29	2017-06-22
2017-02-28	0.29	2017-03-20
2016-12-01	0.29	2016-12-20
2016-08-18	0.29	2016-09-08
2016-05-20	0.29	2016-06-07
2016-02-25	0.29	2016-03-14
2015-11-13	0.29	2015-12-03
2015-08-18	0.29	2015-09-03
2015-05-15	0.29	2015-06-04
2015-02-17	0.29	2015-03-03
2014-11-13	0.27	2014-12-02
2014-08-19	0.29	2014-09-04
2014-05-16	0.30	2014-06-02
2014-02-20	0.29	2014-03-10
2013-11-18	0.28	2013-12-03
2013-08-16	0.27	2013-09-03
2013-05-16	0.27	2013-06-03
2013-02-19	0.27	2013-03-07
2012-11-13	0.20	2012-12-03
2012-08-13	0.21	2012-09-04
2012-05-17	0.20	2012-06-04
2012-02-23	0.20	2012-03-15
2011-11-09	0.17	2011-12-07
2011-08-04	0.20	2011-08-25
2011-05-19	0.20	2011-06-07
2011-02-10	0.22	2011-03-07
2010-11-08	0.17	2010-12-06
2010-08-02	0.17	2010-08-26
2010-05-10	0.16	2010-06-04
2010-02-19	0.16	2010-03-17
2009-11-06	0.13	2009-12-04
2009-08-03	0.12	2009-08-27
2009-05-08	0.12	2009-06-03
2009-02-23	0.11	2009-03-19
2008-11-07	0.09	2008-12-05
2008-08-01	0.10	2008-08-27
2008-05-13	0.11	2008-06-05
2008-02-15	0.10	2008-03-13
2007-11-02	0.08	2007-11-28
2007-08-10	0.08	2007-09-06
2007-05-10	0.08	2007-06-05
2007-02-16	0.08	2007-03-15
2006-11-10	0.07	2006-12-06
2006-08-11	0.06	2006-09-08
2006-05-12	0.06	2006-06-07
2006-03-06	0.06	2006-03-30
2005-11-10	0.05	2005-12-07
2005-08-11	0.05	2005-09-07
2005-05-05	0.06	2005-06-01
2005-02-17	0.06	2005-03-17
2004-11-09	0.04	2004-12-06
2004-08-09	0.04	2004-09-07
2004-05-10	0.15	2004-06-07
2004-02-20	0.08	2004-03-22
2003-11-13	0.06	2003-12-12
2003-08-08	0.06	2003-09-08
2003-05-08	0.06	2003-06-06
2003-02-24	0.05	2003-03-24
2002-11-07	0.07	2002-12-06
2002-08-19	0.07	2002-09-16
2002-05-20	0.07	2002-06-17
2002-02-15	0.08	2002-03-18
2001-11-16	0.05	2001-12-17
2001-08-20	0.05	2001-09-17
2001-05-17	0.05	2001-06-15
2001-03-08	0.05	2001-04-06
2000-11-16	0.04	2000-12-15
2000-08-24	0.04	2000-09-21
2000-05-19	0.04	2000-06-19
2000-02-17	0.08	2000-03-27
1999-11-04	0.05	1999-11-30
1999-08-18	0.05	1999-09-13
1999-05-21	0.05	1999-06-15
1999-03-08	0.05	1999-03-30
1998-11-20	0.05	1998-12-11
1998-08-21	0.06	1998-09-11
1998-05-21	0.06	1998-06-22
1998-03-12	0.06	1998-03-31
1997-11-20	0.07	1997-12-09
1997-08-25	0.07	1997-09-11
1997-05-23	0.07	1997-06-12
1997-03-07	0.07	1997-03-26
1996-11-20	0.05	1996-12-09
1996-08-26	0.05	1996-09-12
1996-05-23	0.05	1996-06-12
1996-03-07	0.05	1996-03-26
1995-11-20	0.05	1995-12-07
1995-08-14	0.05	1995-08-30
1995-05-17	0.05	1995-06-07
1995-03-07	0.05	1995-04-04
1994-11-15	0.05	1994-12-13
1994-08-09	0.05	1994-09-12
1994-05-18	0.05	1994-06-21
1994-03-08	0.05	1994-04-05
1993-11-17	0.04	1994-01-03
1993-08-17	0.04	1993-09-14
1993-05-18	0.03	1993-06-21
1993-04-07	0.06	1993-05-05
1992-11-17	0.04	1992-12-21
1992-08-18	0.04	1992-09-21
1991-11-20	0.04	1991-12-19
1991-08-21	0.04	1991-09-19
1991-05-20	0.04	1991-07-20
1991-03-05	0.04	1991-03-28
1990-11-20	0.04	1990-12-20
1990-08-17	0.04	1990-09-17
1989-05-22	0.04	1989-06-19
1988-12-06	0.04	1988-12-30
1988-09-08	0.04	1988-10-05
1988-06-10	0.03	1988-07-20
1988-04-11	0.03	1988-05-16
1988-02-08	0.03	1988-03-10
1987-10-23	0.03	1987-11-19
1987-07-09	0.04	1987-08-05
1987-06-22	0.03	1987-07-14
1987-02-23	0.03	1987-03-26
1985-09-23	0.02	1985-10-21
1985-06-17	0.02	1985-07-15
1984-01-27	0.02	1984-02-29
1982-08-16	0.40	1982-09-13
1982-08-10	0.06	1982-09-13

公司名稱	梯瓦制药
行業分類	制药
業務描述	Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

梯瓦製藥 TEVA 深 滬

18.35

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

梯瓦製藥 TEVA 深滬